Gene Therapy Briefs

Abstract

Get full access to this article

View all access options for this article.

References

Biogen Idec (2014). Olivier Danos joins Biogen Idec as senior vice president, gene therapy. Available at www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2382&M=NewsV2&PID=61997 (accessed Nov. 7, 2014).

Biogen Idec and Sangamo (2014). Biogen Idec and Sangamo BioSciences announce global collaboration to develop treatments for hemoglobinopathies. Available at http://investor.sangamo.com/releasedetail.cfm?ReleaseID=818108 (accessed Nov. 8, 2014).

Dockser Marcus

(2014). Gene-therapy trial for “bubble boy syndrome” shows promise. The Wall Street Journal, Oct. 8, 2014. Available at http://online.wsj.com/articles/gene-therapy-trial-for-bubble-boy-syndrome-shows-promise-1412802002 (accessed Nov. 8, 2014).

Hacein-Bey-Abina

, Pai

, Gaspar

H.B.

, et al. (2014). A modified γ-retrovirus vector for x-linked severe combined immunodeficiency. NEJM, 371, 1407–1417. Available at www.nejm.org/doi/full/10.1056/NEJMoa1404588 (accessed Nov. 371, 2014).

Mendell

J.R.

, Sahenk

, Malik

, et al. (2014). A phase I/IIa follistatin gene therapy trial for Becker muscular dystrophy. Mol. Ther. DOI: 10.1038/mt.2014.200. Available at www.nature.com/mt/journal/vaop/naam/pdf/mt2014200a.pdf (accessed Nov. 8, 2014).

Milo Biotechnology (2014). Milo Biotechnology's follistatin gene therapy increases function in Becker muscular dystrophy patients. Available at www.prnewswire.com/news-releases/milo-biotechnologys-follistatin-gene-therapy-increases-function-in-becker-muscular-dystrophy-patients-736674961.html (accessed Nov. 7, 2014).

Oxford BioMedica (2013). Oxford BioMedica announces lentiviral vector development and manufacturing collaboration. Available at www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-lentiviral-vector-development-and-manufacturing-collaboration/ (accessed Nov. 7, 2014).

Oxford BioMedica (2014). Oxford BioMedica announces new process development and manufacturing collaboration which includes LentiVector^® licence agreement. Available at www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-new-process-development-and-manufacturing-collaboration-which-includes-lentivector-r-licence-agreemen/ (accessed Nov. 7, 2014).

Unum Therapeutics (2014). Fidelity Biosciences and Atlas Venture lead $12 million series A funding to launch Unum Therapeutics, a new cellular immunotherapy company. Available at www.unumrx.com/#!2014—oct-21—fidelity-biosciences-and/c1cjc (accessed Nov. 8, 2014).